I
IAMA Therapeutics
Makes a difference in the lives of individuals suffering from neurodevelopmental, cognitive disorders
About IAMA Therapeutics
IAMA Therapeutics is a clinical-stage pharmaceutical company, established in 2021 and headquartered in Genoa, Italy. The company emerged from a decade of research conducted at the Italian Institute of Technology (IIT) by the 'Brain Development and Disease' and 'Molecular Modeling and Drug Discovery' research groups, led by founders Laura Cancedda and Marco De Vivo. This foundational research, supported by Fondazione Telethon, focused on neurodevelopmental disorders and led to the discovery of a new class of drug candidates.
The company's core business revolves around discovering and developing small-molecule drugs that target cation-chloride cotransporters to address central nervous system (CNS) disorders. Its business model is centered on advancing these proprietary drug candidates through clinical trials to eventually commercialize them, providing new treatments for patients with neurological conditions. The company has successfully raised a total of $25.9M in capital over two funding rounds. A Series A round in April 2022 brought in €8 million from Claris Ventures and CDP Venture Capital. This was followed by a €15 million Series B round in April 2025, led by Indaco Venture Partners, to accelerate clinical development.
IAMA's lead product candidate is IAMA-6, an orally administered, selective inhibitor of the NKCC1 cotransporter. The NKCC1 protein is involved in transporting chloride ions into neurons; in many brain disorders, its dysregulated activity leads to an ion imbalance and neuronal hyperexcitability. By selectively inhibiting NKCC1, IAMA-6 aims to restore the natural chloride balance and reduce the pathological neuronal activity seen in conditions like epilepsy and autism. This mechanism has shown the potential to alleviate cognitive and behavioral symptoms in preclinical models. IAMA-6 entered a first-in-human Phase 1 clinical trial in January 2024 to evaluate its safety, tolerability, and pharmacokinetics. The company is targeting a range of orphan brain disorders, including drug-resistant epilepsy, Dravet syndrome, and autism spectrum disorders.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 48.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, Health Platform
- Sector
- Veterinary, Biotechnology, Neurology, Spinout, Pets, Hard Tech, DT and LS, science-based
- Business model
- SaaS
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Apr 2025 | $5.5M | $44M | Indaco Venture Partners · CDP Venture Capital · Claris Ventures · Fondazione ENEA Tech | ↗ |
| EARLY VC✓Equity / VC | Mar 2022 | $8.8M | $35M | CDP Venture Capital · Claris Ventures | ↗ |
Growth signals
Latest recorded traffic for IAMA Therapeutics is 790 monthly website visits, up 79.5% over the last three months. IAMA Therapeutics's team grew 11.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
IAMA Therapeutics in the Genoa ecosystem
The IAMA Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
CDP Venture Capital
Claris Ventures
Fondazione ENEA Tech
Indaco Venture Partners
Other known investors1 additional known investor
Italian Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about IAMA Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See IAMA Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









